Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirAVAndrea VisentinLMLeyla Mohseninejad

Discussion

Loading...

Member takes

Overview

Analysis estimates cardiac deaths in CLL patients with ibrutinib versus zanubrutinib, suggesting treatment choice impacts survival.

Key Points

  • To estimate cardiac deaths associated with ibrutinib versus zanubrutinib in chronic lymphocytic leukemia (CLL) patients.
  • Estimated cardiac deaths using a number needed to treat (NNT) model.
  • Calculated NNT based on cardiac death risks from clinical trials.
  • Utilized real-world data to determine the number of CLL patients receiving ibrutinib.
  • Estimated 20 cardiac deaths may have been avoided in 2L CLL patients using zanubrutinib instead of ibrutinib.
  • Sensitivity analysis indicated an avoidance of 19 cardiac deaths in 1L CLL patients with zanubrutinib.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1c8https://doi.org/10.1182/blood-2025-8033
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States2025
  2. 2Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry2026
  3. 3Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort2026 · 4 citations
  4. 4Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies2025
  5. 5Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations